Thrombosis
News
FDA, CDC urge pause of J&J COVID vaccine
Treatment for traditional blood clots, such as the drug heparin, should not be used for these clots.
From the Journals
Novel antiplatelet drug: Hope for efficacy without bleeding?
A new antiplatelet drug with a completely novel mechanism of action could hold the promise of delivering the holy grail – reducing cardiac events...
From the Journals
Study suggests no added risk of blood clots in COVID-19 outpatients
From the Journals
AstraZeneca COVID vaccine: Clotting disorder mechanism revealed?
The vaccine may be linked to a condition that clinically resembles heparin-induced thrombocytopenia and seems to occur mainly in younger women.
From the Journals
New ASH guidelines: VTE prevention and treatment in cancer patients
From the Journals
Large study finds trans men on testosterone at risk for blood clots
Transgender men who take testosterone are at risk of developing erythrocytosis and future thrombotic events, especially if they smoke and are...
News from the FDA/CDC
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)
Completed safety clinical trial shows occurrence of heart-related events and cancer in RA patients taking the Janus kinase inhibitor is higher...
From the Journals
Microthrombi, necrosis seen in COVID-19 hearts on autopsy
A new autopsy series shows microthrombi and focal necrosis in hearts of patients who died of COVID-19. The findings support use of anticoagulation...
Feature
Full-dose anticoagulation reduces need for life support in COVID-19
Conference Coverage
In COVID-19 patients, risk of bleeding rivals risk of thromboembolism
Conference Coverage
A 4-point thrombocytopenia score was found able to rule out suspected HIT